Ziopharm Oncology to Report Second Quarter Financial Results on August 9, 2021
Ziopharm Oncology, Inc. (ZIOP) announced a conference call and webcast on August 9, 2021, at 4:30 p.m. EDT to discuss its second-quarter financial results ending June 30, 2021. The call can be accessed via phone or through a live webcast available on the company’s website. Ziopharm focuses on developing innovative non-viral and cytokine-driven cell and gene therapies aimed at treating cancer. Their strategy includes partnerships with prominent institutions like the National Cancer Institute and Regeneron Pharmaceuticals.
- Partnerships with leading institutions enhance research capabilities.
- Focus on innovative, scalable cancer therapies could drive future growth.
- None.
BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021.
The conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or 201-389-0879 (International). The passcode for the conference call is 13721210. A live webcast may be accessed using the link here, or by visiting the “Investors” section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Company’s website for approximately 90 days after the call.
About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with cancer each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology. Ziopharm’s pipeline is built for commercially scalable, cost-effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit www.ziopharm.com.
Investor Relations Contact:
Adam D. Levy, Ph.D., MBA
EVP, Corporate Development and Investor Relations
T: 508.552.9255
E: alevy@ziopharm.com
FAQ
When will Ziopharm Oncology announce its Q2 financial results?
What is the stock symbol for Ziopharm Oncology?
How can I listen to the Ziopharm conference call?
What is Ziopharm Oncology's focus in cancer treatment?
